OASIS PHARMACEUTICALS, LLC
Biotech · Private
GPR31 antagonist pepducin therapeutic for stroke prevention and treatment
- Grants
- $11M
- 19 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 2 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis | $871,014 | |
| Federal grant | Department of Health and Human Services · Phase II · Supplement to grant 5R42DK101240 Oasis Pharmaceuticals to attend BIO conference | $5,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $750,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of PAR4 Pepducins as a Novel Antithrombotic Treatment | $366,484 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of PAR Pepducins as a Novel Antithrombotic Treatment | $366,484 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $750,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins as a Novel NASH Treatment | $1,048,644 | |
| Federal grant | Department of Health and Human Services · Phase II · PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $225,769 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins as a Novel NASH Treatment | $1,060,598 | |
| Federal grant | Department of Health and Human Services · Phase II · PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $750,502 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of PAR2 Pepducins as a Novel NASH Treatment | $1,056,106 | |
| Federal grant | Department of Health and Human Services · Phase II · PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $740,572 | |
| Federal grant | Department of Health and Human Services · Phase I · Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $361,774 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma | $392,485 | |
| Federal grant | Department of Health and Human Services · Phase II · Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $999,799 | |
| Federal grant | Department of Health and Human Services · Phase II · Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $999,799 | |
| Federal grant | Department of Health and Human Services · Phase II · Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $50,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of PAR2 Pepducins for the Treatment of COPD | $468,369 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1317 | CADRE BIOSCIENCE, LLC | — | — |
| 1318 | BOTANISOL, LLC | — | — |
| 1319 | ONCA BIO, INC. | — | — |
| 1320 | OASIS PHARMACEUTICALS, LLC | — | — |
| 1321 | DRIVE THERAPEUTICS, L.L.C. | — | — |
| 1322 | Morphic Therapeutic | — | — |
| 1323 | LEFLORE TECHNOLOGIES LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Protease-activated RECEPTOR-2 Modulatorsgranted
- Protease-activated RECEPTOR-2 Modulatorsgranted
- Protease-activated RECEPTOR-2 Modulatorsapplication
- Protease-activated RECEPTOR-2 Modulatorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.